Non-Hodgkin's Lymphoma Clinical Trials

A listing of Non-Hodgkin's Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 115 clinical trials
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US  

Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL

  • 1875 views
  • 01 Dec, 2020
  • 15 locations
featured
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma

Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma

  • 590 views
  • 23 Nov, 2020
  • 5 locations
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept (ACE-536) …

cancer
erythropoietin
epoetin alfa
vasectomy
  • 53 views
  • 24 Nov, 2020
  • 7 locations
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.

apheresis
neutrophil count
b-cell lymphoma
rituximab
marginal zone lymphoma
  • 48 views
  • 25 Nov, 2020
  • 69 locations
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

The purpose of the study is to assess the efficacy and safety of tisagenlecleucel in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). For pediatric

hodgkin's disease
measurable disease
large b-cell lymphoma
neutrophil count
b-cell lymphoma
  • 6 views
  • 01 Dec, 2020
  • 34 locations
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This is a dose escalating study to define the maximum tolerable dose of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) in DLBCL patients who are not eligible for autologous stem cell transplant. The study …

renal function
large b-cell lymphoma
neutrophil count
high-dose chemotherapy
thromboplastin
  • 0 views
  • 02 Dec, 2020
  • 7 locations
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3K inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy

ejection fraction
ct scan
refractory follicular lymphoma
follicular lymphoma
marginal zone lymphoma
  • 127 views
  • 18 Nov, 2020
  • 142 locations
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO)

This study will examine the effects of predefined 2 week duvelisib dose holidays on tumor responses and safety/tolerability.

  • 1 views
  • 22 Nov, 2020
  • 42 locations
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

) and the Scandinavian NOPHO group (Denmark, Finland, Norway, Sweden). The aim of the trial is to evaluate the role of rituximab in the treatment of mature aggressive B-cell Non-Hodgkin lymphoma and

  • 494 views
  • 30 Nov, 2020
  • 93 locations
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).

hodgkin's disease
cyclophosphamide
residual disease
tyrosine
oximetry
  • 0 views
  • 20 Nov, 2020
  • 34 locations